Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05346809 · ClinicalTrials.gov registry record · Phase 2

Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma

A Phase 2 study of Multiple Myeloma and Lymphoma, sponsored by Divaya Bhutani.

Recruiting
Registry status
Phase 2
Development phase
39
Enrollment target
2
Study locations

NCT05346809 is a Phase 2 study of Multiple Myeloma and Lymphoma that is actively recruiting participants, run by Divaya Bhutani. The registered enrollment target is 39 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05346809, a Phase 2 study of Multiple Myeloma and Lymphoma, is actively recruiting participants, sponsored by Divaya Bhutani.

RECRUITING
Registry status
Phase 2
Development phase
39 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to see if Isatuximab can alter the immune system in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. The investigators will see if Isatuximab makes changes to the immune system so that upon recovery from the transplant, the immune system can fight the cancer. This study will have two arms. On one arm (control arm), participants will receive standard transplant procedures and on the other arm (experimental arm), participants will receive Isatuximab in addition to the standard transplant procedures. The assignment to these arms is done randomly (determined by chance, like flipping a coin) by a computer. Each participant will have about 66% chance of getting on the experimental arm and about 33% chance of getting on the control arm.

Conditions Studied

Multiple Myeloma Lymphoma Non-Hodgkin Lymphoma Relapsed Hodgkin's Disease, Adult

Interventions

  • DRUG Isatuximab
  • OTHER Standard Procedures

Study Locations (2)

Michigan

  • Karmanos Cancer Institute - Detroit

New York

  • Columbia University - New York

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2023-03-31
Est. Completion 2026-09
Phase Phase 2

Sponsor

Divaya Bhutani

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05346809

The ClinicalTrials.gov registry entry for NCT05346809 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (93% lower). The listed sponsor is Divaya Bhutani, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Isatuximab is the first listed.

NCT05346809 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Michigan, New York.

Frequently Asked Questions

What is clinical trial NCT05346809 about?

NCT05346809 is a clinical study titled "Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma". The purpose of this study is to see if Isatuximab can alter the immune system in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. The investigators will see if Isatuximab makes changes to the immune system so that upon recovery from the transpla...

What is the current status of trial NCT05346809?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2023-03-31. Estimated completion is 2026-09.

What conditions does trial NCT05346809 study?

This clinical trial studies the following conditions: Multiple Myeloma, Lymphoma, Non-Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult.

What interventions are being tested in trial NCT05346809?

The interventions under investigation include: Isatuximab (DRUG), Standard Procedures (OTHER).

Who is sponsoring clinical trial NCT05346809?

This trial is sponsored by Divaya Bhutani, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05346809 being conducted?

This trial has 2 study locations across Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Lymphoma

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.